By Brian Kennedy, Executive Director of the Global Alliance for Patient Access When should patients switch from one medicine to another for non-medical reasons? How can
Physician organization urges lawmakers to prioritize access to safe, approved medications. WASHINGTON – The Alliance for Patient Access (AfPA) made the following statement about the amendment
“Doctor, make my pain go away.” I hear this plea, in one form or another, from patients on a daily basis. Yet it presents physicians like
What can the federal government do to raise clinical trials awareness? Maybe a lot, suggests one organization. May 1-5 marks Clinical Trials Awareness Week, when
National health plan report card analyzes PCSK9 inhibitor claims for managed care organizations WASHINGTON – The Institute for Patient Access released a new National Health
Rejection is never pleasant. But for the 34,459 patients whose health plans refuse to cover advanced treatment for high cholesterol, it could also be deadly.
White paper addresses current policy issues impacting biosimilars including naming, interchangeability, and labeling and reimbursement policies WASHINGTON – Today the Biologics Prescribers Collaborative (BPC), a project
WASHINGTON – Tomorrow, April 27, the Biologics Prescribers Collaborative (BPC), a project of the Alliance for Patient Access, will host a congressional briefing on Capitol Hill